What changes are needed to the current direction and interpretation of clinical cancer research to meet the needs of the 21st century?

Matthew P Doogue and Kathleen M Knights
Med J Aust 2009; 191 (3): . || doi: 10.5694/j.1326-5377.2009.tb02742.x
Published online: 3 August 2009

To the Editor: Articles by Olver and Haines1,2 have catalysed robust discussion about the relationship between the pharmaceutical and device industries and the medical profession.3 These authors advocate changes in the direction of clinical cancer research and in health policy.2 In an era in which research into medicines is dominated by industry, they argue for greater scrutiny of data in a resource-constrained environment, and for fundamental changes in the collection, interpretation and ownership of data. We find their arguments sound and equally applicable to other areas of medicines research and health policy.

  • Matthew P Doogue
  • Kathleen M Knights

  • Australasian Society of Clinical and Experimental Pharmacologists and Toxicologists (ASCEPT), Adelaide, SA.


remove_circle_outline Delete Author
add_circle_outline Add Author

Do you have any competing interests to declare? *

I/we agree to assign copyright to the Medical Journal of Australia and agree to the Conditions of publication *
I/we agree to the Terms of use of the Medical Journal of Australia *
Email me when people comment on this article

Online responses are no longer available. Please refer to our instructions for authors page for more information.